Back to state act
Description
On 30 September 2025, the U.S. Administration announced reaching an agreement with Pfizer Inc. Under the agreement, Pfizer will be exempt from future Section 232 tariffs on pharmaceutical products for...
Sign in or create a free account to see full description
Intervention Details
Intervention Type
Tax or social insurance relief
MAST Chapter
L: Subsidies (excl. export subsidies)
Implementation date
No implementation date
Revocation date
No revocation date
Implementation level
National
Affected flow
Inward
Announced as temporary
No
Eligible firms
firm-specific
Affected Trading Partners
Table
Affected Sectors
Sign in to access 2 sectors
Affected Products
Sign in to access 11 products
Threads
See all
Harmful Trade Policy Measures
This Thread tracks harmful trade policy interventions affecting all products. Covering all types of interventions monitored by Global Trade Alert, it highlights how the yearly number of these measures has evolved over time.
Published: 04 Sep 2024
70619
interventions
194
jurisdictions
United States: Drug Pricing Agreements
This Thread tracks the U.S. Administration’s agreements with pharmaceutical companies. It is based on the Executive Order titled “Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.” These agreements include tariff relief measures for pharmaceutical companies in return for their commitments to implement most-favored-nation pricing for their drugs and to invest i...
Published: 11 Nov 2025
68
interventions
2
jurisdictions